US1928346A - Anaesthetic - Google Patents
Anaesthetic Download PDFInfo
- Publication number
- US1928346A US1928346A US500427A US50042730A US1928346A US 1928346 A US1928346 A US 1928346A US 500427 A US500427 A US 500427A US 50042730 A US50042730 A US 50042730A US 1928346 A US1928346 A US 1928346A
- Authority
- US
- United States
- Prior art keywords
- ether
- acid
- ethyl
- mixture
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003444 anaesthetic effect Effects 0.000 title description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- 150000001875 compounds Chemical class 0.000 description 20
- 229940125717 barbiturate Drugs 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 11
- 230000000147 hypnotic effect Effects 0.000 description 10
- 239000002480 mineral oil Substances 0.000 description 10
- 235000010446 mineral oil Nutrition 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 235000001258 Cinchona calisaya Nutrition 0.000 description 6
- STDBAQMTJLUMFW-UHFFFAOYSA-N butobarbital Chemical compound CCCCC1(CC)C(=O)NC(=O)NC1=O STDBAQMTJLUMFW-UHFFFAOYSA-N 0.000 description 6
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 6
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 6
- 229960000948 quinine Drugs 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940105631 nembutal Drugs 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 208000007914 Labor Pain Diseases 0.000 description 2
- 208000035945 Labour pain Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229940124326 anaesthetic agent Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- -1 barbituric compound Chemical class 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- GFPIGNBQTXNNAG-UHFFFAOYSA-N 5-propan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound CC(C)C1C(=O)NC(=O)NC1=O GFPIGNBQTXNNAG-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229960000880 allobarbital Drugs 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 229940124327 inhalation anaesthetic agent Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- HHLXJTDUHFBYAU-UHFFFAOYSA-N probarbital Chemical compound CCC1(C(C)C)C(=O)NC(=O)NC1=O HHLXJTDUHFBYAU-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000005061 slumber Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
Definitions
- morphine or similar narcotics In actual use, the patient is first given enemas administrations are apt to have an undesired until the return is clear, after which the barbieilect upon the patient and the child and does not turic preparation is instilled. The instillation of always serve the intended purpose.
- the barbituric compound may be preceded by an It is therefore one of the objects of my invenounce of plain oil, also Vaseline is applied to the 70 tion to provide a hypnotic compound which may anus to prevent possible irritation should the be administered to the patient in the first stage compound be expelled.
- the compound may include a mixture of vide an anasthetic which may be easily and safemineral oil, ether, quinine and a barbiturate.
- the ly administered to the patient and which tends to oil used may be either a mineral oil or vegetable eliminate the nervous condition which sometimes 011 uc a Olive HOWEVBI', mineral Oil is p accompany the administration of anaesthetics. fcrred as it does not tend to turn rancid.
- Another object of my invention is to provide an also to be understood that the proportions of anaesthetic which may be administered during the the ingredients in the compound may be varied first stages of labor and which is sufliciently lastto procure difierent degrees of anaesthesia. ing in its efiects to maintain the patient under I have observed in my various experiences at its analgesic influence throughout the entire dethe solution can be made either with or without 1ivery the aid of solvents other than the ether.
- ethyl (lmethylbutyl) barbituric acid is representative of a quick acting barbiturate which takes effect very shortly after administration, whereas the other is representative of a relatively slow acting barbiturate which in this instance may involve twice as much time before it becomes effective.
- This mixture may be administered as previously described and is particularly adaptable for analgesia during childbirth.
- the average patient Upon instillation of the above dosage, the average patient is susceptible to from 10 to 18 hours of complete amnesia and analgesia.
- a compound made in accordance with my invention, from which the quinine is omitted may also be used for surgery.
- a particular combination for such use may be 2% ounces ether, 1%; ounces mineral oil and 10 grains of nembutal. It is very apparent-that the increased proportions of the barbiturate will give more complete anaesthesia.
- the dosage may be regulated according to body Weight, a patient weighing 130 pounds or over receiving the full 4 ounce mixture; those between 100 and 130 pounds receiving approximately of the contents and those under 100 pounds receiving /2 of the contents.
- a hypnotic compound for rectal instillation comprising a solution of oil, ether and a barbiturate.
- a hypnotic compound for rectal instillation comprising a mixture of oil and ether and an oil and ether soluble barbiturate.
- a hypnotic compound for rectal instillation comprising a mixture of mineral oil and ether and an oil and ether soluble barbiturate.
- a hypnotic compound for rectal instillation comprising a mixture of mineral oil and ether and a barbiturate.
- a hypnotic compound for rectal instillation comprising a mixture of oil, ether and two or more of the barbiturates.
- a hypnotic compound for rectal instillation comprising a mixture of oil, ether and oil and ether soluble barbiturates.
- a hypnotic compound for rectal instillation comprising a mixture of oil, ether, and ethyl (1-methyl butyl) barbituric acid-and n-butylethyl-barbituric-acid.
- a hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and ethyl (l-methyl butyl) barbituric-acid.
- A-hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and n-butylethylbarbituric-acid.
- a hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and ethyl (l-methyl butyl) barbituric-acid and n-butyl-ethyl-barbituric-acid.
- An analgesic comprising a mixture in the proportions-mineral oil 1 /2 ounces, ether 2%; ounces, and ethyl (l-methyl butyl) barbituricacid 8 grains and n-butyl-ethyl-barbituric-acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Patented Sept. 26. 1933 1 1,928,346
ANZESTHETIC Meyer L. Axelrod, Cleveland, Ohio, assignor of gfltiy per cent to Harry Fraiberg, Cleveland,
No Drawing. Application December 5, 1930 Serial No. 500,427
12 Claims. (Cl. 167-52) My invention relates to improvements in hyp- Phanodorn cyclohexenyl ethyl barbiturio notic compounds, particularly analgesics and acid. anaesthetics. In the administration of anaes- Amytal-isoamyl ethyl barbituric acid.
thetics or analgesics, particularly for obstetrical Ipral (acid form)-ethyl isopropyl barbituric operations, the usual practice has been to await acid.
until a certain amount of dilation of the cervix Pernokton-secondary butyl bromallyl barbihas taken place before administering the particuturic acid. lar anaesthetic. It is common knowledge that the Phenobarbital-phenyl ethyl barbituric acid labor pains prior to the aforesaid dilation are (Luminal).
0 excruciating but may be relieved by the use of Barbital-diethyl barbituric acid (Veronal). 65
morphine or similar narcotics. However, such In actual use, the patient is first given enemas administrations are apt to have an undesired until the return is clear, after which the barbieilect upon the patient and the child and does not turic preparation is instilled. The instillation of always serve the intended purpose. the barbituric compound may be preceded by an It is therefore one of the objects of my invenounce of plain oil, also Vaseline is applied to the 70 tion to provide a hypnotic compound which may anus to prevent possible irritation should the be administered to the patient in the first stage compound be expelled. A slow uniform rate of of labor to permit uterine contractions and relieve instillation is established and the mixture perthe initial pains as well as the pains in the other mitted to enter the colon between uterine constages of labor. traCtiOnS- 5 Still another object of my invention is to pro- The compound may include a mixture of vide an anasthetic which may be easily and safemineral oil, ether, quinine and a barbiturate. The ly administered to the patient and which tends to oil used may be either a mineral oil or vegetable eliminate the nervous condition which sometimes 011 uc a Olive HOWEVBI', mineral Oil is p accompany the administration of anaesthetics. fcrred as it does not tend to turn rancid. It is I am aware that ether and oil with quinine have may be more quickly put into solution by using a Another object of my invention is to provide an also to be understood that the proportions of anaesthetic which may be administered during the the ingredients in the compound may be varied first stages of labor and which is sufliciently lastto procure difierent degrees of anaesthesia. ing in its efiects to maintain the patient under I have observed in my various experiences at its analgesic influence throughout the entire dethe solution can be made either with or without 1ivery the aid of solvents other than the ether. In
Still other objects and uses of my new comsome ether the alcohol content is relatively high pound will become apparent from the following and therefore the quinine is more expeditiously description thereof. put into solution. I also find that the quinine been heretofore administered to the patient by small amount of other solvents, such as ethyl rectal instillation for obtaining analgesia; howalcohol, and when so used, I find that approxiever, as previously stated, this administration mately three fluid drains of ethyl alcohol in a cannot be applied with success to the patient unfour fluid ounce solution of the compound is sufiitil after the first stages of labor have passed becient for all purposes of solubility. cause of the short duration of its eflect. I am I have found that a mixture of 1 ounces also aware that barbiturates have been used with mineral oil, 2 ounces ether, 20 grains quinine inhalation anaesthetics. I believe the use of the alkaloid, together with a mixture of two barbitubarbiturates in the manner which I am about to rates which are known to the profession as disclose, is distinctly new. There are at the presnembutal (acid form) and neonal, which barbi- 190 ent time, a number of commercial barbiturates, u a s a et y (l-mcthyl y barbitulic some of which better suit themselves than others, acid, and n-butyl ethyl barbituric acid respecto my particular compound. Among the more tively, in the proportion of 8 grains nembutal useful barbiturates I have used are the following: (acid form) and 5 grains neonal produce a very 0 Nembutal (acid form)-ethyl (l-methyl butyl) satisfactory result. I find that a combination barbituric acid. of two or more barbiturates as described is some- Neonaln-butyl ethyl barbituric acid. times desirable. The effect is not additive but Allonala1lyl isopropyl barbituric acid plus due to the synergetic action between the two bar- 5 amidopyrine. biturates, each barbiturate enhances the action o Dial-diallyl barbituric acid. of the other, causing a substantially different eifect than is found from the use of either one alone. In the foregoing example ethyl (lmethylbutyl) barbituric acid is representative of a quick acting barbiturate which takes effect very shortly after administration, whereas the other is representative of a relatively slow acting barbiturate which in this instance may involve twice as much time before it becomes effective. This mixture may be administered as previously described and is particularly adaptable for analgesia during childbirth. Upon instillation of the above dosage, the average patient is susceptible to from 10 to 18 hours of complete amnesia and analgesia.
A compound made in accordance with my invention, from which the quinine is omitted may also be used for surgery. A particular combination for such use may be 2% ounces ether, 1%; ounces mineral oil and 10 grains of nembutal. It is very apparent-that the increased proportions of the barbiturate will give more complete anaesthesia. The dosage may be regulated according to body Weight, a patient weighing 130 pounds or over receiving the full 4 ounce mixture; those between 100 and 130 pounds receiving approximately of the contents and those under 100 pounds receiving /2 of the contents.
In actual use it has been found that the patient usually becomes drowsy within 30 minutes and gradually goes into a deep slumber. In time, (1 hour) most patients can be aroused but with great difliculty and the uterine contractions appear to be accelerated rather than interfered with. The dosage of the barbiturates may in some cases be regulated in such a manner that a supplemental anaesthesia may be required. The use of a compound as described, eliminates the use of drugs which may seriously afiect the baby or patient. It will also reduce the post operative need of narcotics. The pulse, respiration and blood pressure are not materially affected. The blood loss is not affected. Uterine contractions are not interfered with and the patient has no recollection of labor pains. No undesirable after effects have been observed.
Having thus described my compound and its method of use, I am aware that the exact proportions of the various ingredients may be varied, and should be varied to suit different cases, but
that such variation is well within the precepts of the invention and such as may be understood to those experienced in such matters and does not depart from the spirit of myinvention nor the scope of the appended claims.
I claim:
1. A hypnotic compound for rectal instillation comprising a solution of oil, ether and a barbiturate.
2. A hypnotic compound for rectal instillation comprising a mixture of oil and ether and an oil and ether soluble barbiturate.
3. A hypnotic compound for rectal instillation comprising a mixture of mineral oil and ether and an oil and ether soluble barbiturate.
4. A hypnotic compound for rectal instillation comprising a mixture of mineral oil and ether and a barbiturate.
5. A hypnotic compound for rectal instillation comprising a mixture of oil, ether and two or more of the barbiturates.
6 A hypnotic compound for rectal instillation comprising a mixture of oil, ether and oil and ether soluble barbiturates.
7. A hypnotic compound for rectal instillation comprising a mixture of oil, ether, and ethyl (1-methyl butyl) barbituric acid-and n-butylethyl-barbituric-acid.
8. A hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and ethyl (l-methyl butyl) barbituric-acid.
9. A-hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and n-butylethylbarbituric-acid.
10. A hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and ethyl (l-methyl butyl) barbituric-acid and n-butyl-ethyl-barbituric-acid.
11. An analgesic comprising a mixture in the proportions-mineral oil 1 /2 ounces, ether 2%; ounces, and ethyl (l-methyl butyl) barbituricacid 8 grains and n-butyl-ethyl-barbituric-acid
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US500427A US1928346A (en) | 1930-12-05 | 1930-12-05 | Anaesthetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US500427A US1928346A (en) | 1930-12-05 | 1930-12-05 | Anaesthetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US1928346A true US1928346A (en) | 1933-09-26 |
Family
ID=23989371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US500427A Expired - Lifetime US1928346A (en) | 1930-12-05 | 1930-12-05 | Anaesthetic |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US1928346A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2603583A (en) * | 1949-03-04 | 1952-07-15 | Welch Henry | Pectin penicillin preparation |
| US2619447A (en) * | 1949-03-11 | 1952-11-25 | American Cyanamid Co | Injectable penicillin preparations |
| US2736682A (en) * | 1954-10-11 | 1956-02-28 | Victor M Hermelin | Method of making a prolonged action medicinal tablet |
| US2793979A (en) * | 1953-03-30 | 1957-05-28 | Smith Kline French Lab | Method of making a sustained release pharmaceutical tablet and product of the method |
| US2824546A (en) * | 1950-10-20 | 1958-02-25 | Klette Hermann | Treating animals with hormone preparation |
| US2839447A (en) * | 1955-01-07 | 1958-06-17 | Riedelde Haen Ag | Intravenous ultrashort-acting anesthetic composition |
| US3075983A (en) * | 1963-01-29 | -oconh | ||
| US3108997A (en) * | 1957-10-31 | 1963-10-29 | Astra Ab | Morpholino lower alkanoyl xylidides and toluidides |
| US5252577A (en) * | 1992-03-06 | 1993-10-12 | Gillette Canada, Inc. | Methods of desensitizing teeth |
| US5660817A (en) * | 1994-11-09 | 1997-08-26 | Gillette Canada, Inc. | Desensitizing teeth with degradable particles |
-
1930
- 1930-12-05 US US500427A patent/US1928346A/en not_active Expired - Lifetime
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075983A (en) * | 1963-01-29 | -oconh | ||
| US2603583A (en) * | 1949-03-04 | 1952-07-15 | Welch Henry | Pectin penicillin preparation |
| US2619447A (en) * | 1949-03-11 | 1952-11-25 | American Cyanamid Co | Injectable penicillin preparations |
| US2824546A (en) * | 1950-10-20 | 1958-02-25 | Klette Hermann | Treating animals with hormone preparation |
| US2793979A (en) * | 1953-03-30 | 1957-05-28 | Smith Kline French Lab | Method of making a sustained release pharmaceutical tablet and product of the method |
| US2736682A (en) * | 1954-10-11 | 1956-02-28 | Victor M Hermelin | Method of making a prolonged action medicinal tablet |
| US2839447A (en) * | 1955-01-07 | 1958-06-17 | Riedelde Haen Ag | Intravenous ultrashort-acting anesthetic composition |
| US3108997A (en) * | 1957-10-31 | 1963-10-29 | Astra Ab | Morpholino lower alkanoyl xylidides and toluidides |
| US5252577A (en) * | 1992-03-06 | 1993-10-12 | Gillette Canada, Inc. | Methods of desensitizing teeth |
| US5660817A (en) * | 1994-11-09 | 1997-08-26 | Gillette Canada, Inc. | Desensitizing teeth with degradable particles |
| US5741479A (en) * | 1994-11-09 | 1998-04-21 | Gillette Canada Inc. | Desensitizing teeth with degradable particles |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hollander et al. | Hydrocortisone and cortisone injected into arthritic joints: comparative effects of and use of hydrocortisone as a local antiarthritic agent | |
| Forster et al. | IV midazolam as an induction agent for anaesthesia: a study in volunteers | |
| SADOVE et al. | Analgesic effects of ketamine administered in subdissociative doses | |
| AMATRUDA JR et al. | A study of the mechanism of the steroid withdrawal syndrome. Evidence for integrity of the hypothalamicpituitary-adrenal system | |
| US1928346A (en) | Anaesthetic | |
| Dundee et al. | Comparison of the actions of diazepam and lorazepam | |
| Hamilton et al. | Expectorant action of bromhexine in chronic obstructive bronchitis | |
| Eger et al. | Etiology of varicose veins from an anatomic aspect, based on a dissection of thirty-eight adult cadavers | |
| Godlowski | Eosinopenia caused by Adrenaline and Insulin | |
| Redfern et al. | Incremental propofol for short procedures | |
| Bishop et al. | Treatment of functional menstrual disorders with norethisterone | |
| Jayson et al. | Popliteal and calf cysts in rheumatoid arthritis. Treatment by anterior synovectomy | |
| FRIEDMAN et al. | THE HYPERTENSIVE EFFECT OF COMPOUND FACETATE (17-OH-CORTICOSTERONE-21-ACETATE) IN THfi RAT | |
| Markowitz et al. | The rôle of the liver and other abdominal viscera in the destruction of epinephrin in the body | |
| DD238921A5 (en) | METHOD FOR PRODUCING A CONTRAZEPTIVE SYNERGISTIC COMPOSITION | |
| Grossman et al. | The pepsin content of gastric juice secreted in response to hormonal stimulation | |
| Roby et al. | Demerol (S-140) and scopolamine in labor: A preliminary report | |
| US3108041A (en) | Antitussive compositions | |
| Minard et al. | Thymoxyethyldiethylamine antagonism to circulatory effects of histamine in anesthetized and nonanesthetized dogs | |
| JPH06166629A (en) | Improver for atopic dermatitis | |
| OLIVER-GONZÁLEZ et al. | TREATMENT OF FILARIASIS BANCROFTI WITH HETRAZAN®: Follow-up Observations Fifteen Months After Treatment | |
| FRIEDGOOD | Similarity of the iodin remission in experimental anterior hypophyseal hyperthyroidism, the hyperthyroidism of acromegaly and that of exophthalmic goiter | |
| MILLS et al. | Observations on acute leukemia in children treated with 4-aminopteroylglutamic acid | |
| Helfrich et al. | Cortical extract in the treatment of shock: Preliminary report | |
| DUNDEE et al. | CLINICAL STUDIES OF INDUCTION AGENTS XX: A METHOHEXITONE-PROPANIDID MIXTURE |